SCHEMBL4587822

SCHEMBL4587822

CC(=O)N[C@@H](CSCC(=O)C(=O)OCC(C)(C)CO[N+](=O)[O-])C(=O)O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.36
ALDH1A1 P00352 2/20 0.36
PPARG P37231 4/20 0.35
PPARA Q07869 4/20 0.35
SMN1; SMN2 Q16637 2/20 0.33
ACE P12821 1/20 0.33
KDM4E B2RXH2 1/20 0.33
THRB P10828 1/20 0.33
ALOX15 P16050 1/20 0.33
NFKB1 P19838 1/20 0.33
PTGS2 P35354 1/20 0.33
THPO P40225 1/20 0.33
RECQL P46063 1/20 0.33
BLM P54132 1/20 0.33
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
HTT P42858 1/20 0.32
ICMT O60725 2/20 0.30
PPARD Q03181 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4587129 0.87 MAPT (0.35) MAPTALDH1A1PPARGPPARASMN1; SMN2
SCHEMBL4587770 0.84 MAPT (0.36) MAPTALDH1A1PPARGPPARASMN1; SMN2
SCHEMBL4587221 0.83 CYP1A2 (0.33) SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT
SCHEMBL4587226 0.83 CYP1A2 (0.33) SMN1; SMN2CYP1A2CYP2C9CYP2C19HTT
SCHEMBL4588714 0.82 NOS2 (0.33) ALDH1A1
SCHEMBL4588333 0.81 ALDH1A1 (0.37) ALDH1A1SMN1; SMN2CYP1A2CYP2C9CYP2C19
SCHEMBL4588338 0.81 ALDH1A1 (0.37) ALDH1A1SMN1; SMN2CYP1A2CYP2C9CYP2C19
SCHEMBL4586125 0.81 MAPT (0.37) MAPTALDH1A1PPARGPPARASMN1; SMN2
SCHEMBL4585907 0.81 MAPT (0.37) MAPTALDH1A1PPARGPPARASMN1; SMN2
SCHEMBL4586511 0.79 NOD1 (0.35)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080287407-A1 Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use NITROMED, INC. (US) 2008-11-20 US claimed
EP-1692107-A4 NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2008-10-29 EP claimed
EP-1692107-A2 NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE Nitromed, Inc. (US) 2006-08-23 EP claimed
WO-2005060603-A2 NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2005-07-07 WO claimed
US-20080287407-A1 Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use NITROMED, INC. (US) 2008-11-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287407-A1 Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use PC, PDK1, NOS3 MAPT 3734/4885ALDH1A1 567/4885PPARG 532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.